Signaling Pathways of the Insulin-like Growth Factor Binding Proteins
Endocrine Reviews · 15.09.2023 · 44 (5) · 753-778
DOI: 10.1210/endrev/bnad008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine Reviews, online erschienen am 28.03.2023. Verfasst von Robert C Baxter. Beteiligte Einrichtung: Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St Leonards, NSW 2065, Australia. Hauptthemen laut MEDLINE: Insulin-Like Growth Factor Binding Proteins, Insulin-Like Growth Factor I. Die Arbeit wurde bisher 165-mal zitiert (Crossref) und nennt 313 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The 6 high-affinity insulin-like growth factor binding proteins (IGFBPs) are multifunctional proteins that modulate cell signaling through multiple pathways. Their canonical function at the cellular level is to impede access of insulin-like growth factor (IGF)-1 and IGF-2 to their principal receptor IGF1R, but IGFBPs can also inhibit, or sometimes enhance, IGF1R signaling either through their own post-translational modifications, such as phosphorylation or limited proteolysis, or by their interactions with other regulatory proteins. Beyond the regulation of IGF1R activity, IGFBPs have been shown to modulate cell survival, migration, metabolism, and other functions through mechanisms that do not appear to involve the IGF-IGF1R system. This is achieved by interacting directly or functionally with integrins, transforming growth factor β family receptors, and other cell-surface proteins as well as intracellular ligands that are intermediates in a wide range of pathways. Within the nucleus, IGFBPs can regulate the diverse range of functions of class II nuclear hormone receptors and have roles in both cell senescence and DNA damage repair by the nonhomologous end-joining pathway, thus potentially modifying the efficacy of certain cancer therapeutics. They also modulate some immune functions and may have a role in autoimmune conditions such as rheumatoid arthritis. IGFBPs have been proposed as attractive therapeutic targets, but their ubiquity in the circulation and at the cellular level raises many challenges. By understanding the diversity of regulatory pathways with which IGFBPs interact, there may still be therapeutic opportunities based on modulation of IGFBP-dependent signaling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St Leonards, NSW 2065, Australia.
ORCID-Profile: Robert C Baxter
Zitieren
APA
Baxter, R. C. (2023). Signaling Pathways of the Insulin-like Growth Factor Binding Proteins. Endocrine Reviews, 44(5), 753-778. https://doi.org/10.1210/endrev/bnad008
Vancouver
Baxter RC. Signaling Pathways of the Insulin-like Growth Factor Binding Proteins. Endocrine Reviews. 2023;44(5):753-778. doi:10.1210/endrev/bnad008
BibTeX
@article{Baxter2023,
author = {Baxter, Robert C},
title = {Signaling Pathways of the Insulin-like Growth Factor Binding Proteins},
journal = {Endocrine Reviews},
year = {2023},
volume = {44},
number = {5},
pages = {753--778},
doi = {10.1210/endrev/bnad008}
}
EUVIMED